Info

Embrex, a wholly-owned subsidiary of Pfizer Inc. is an international agricultural biotechnology company focused on developing patented biological and mechanical products that improve bird health, reduce bird and production costs and provide other economic benefits to the poultry industry. The company has developed and commercialized the first in ovo platform delivery system called the Inovoject® system, a proprietary, automated, injection system which eliminates the need for manual vaccination of newly hatched broiler chicks. Since its commercial introduction in 1993, what was once revolutionary has become an industry standard. Today the Inovoject® system is used to vaccinate more than 80 percent of the birds raised in North America against Marek's disease. A much smaller percentage of North American broiler birds is also being vaccinated in ovo against infectious bursal disease (IBD) with Embrex's USDA approved product, Bursaplex®. Inovoject® systems also have been placed or are being tested in Europe, the United Kingdom, the Middle East, Asia, Australia, Latin America and Africa. Scientists and engineers at Embrex are innovators in their field, working independently and with partners to develop new in ovo products. The company continues to focus on developing and commercializing patented biological, mechanical and data management products that improve bird health, reduce bird production costs and provide other economic benefits to the global poultry industry. The potential of Embrex's technology is significant. The corporate mission is clear: to provide ever increasing value to the global poultry industry via in ovo-based products.